Home > Insider Trading > Filing (0001209191-20-046812)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
920465	La Jolla Pharmaceutical Co	LJPC	Biological Products, (No Disgnostic Substances) (2836)	330361285

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1178579	C Kevin Tang	4747 Executive Drive, Suite 210 San Diego CA 92121		Yes	No	Yes	No
1191935	Tang Capital Partners Lp	4747 Executive Drive, Suite 210 San Diego CA 92121		No	No	Yes	No
1232621	Tang Capital Management Llc	4747 Executive Drive, Suite 210 San Diego CA 92121		No	No	Yes	No
1759910	S Michael Hearne	4747 Executive Drive, Suite 210 San Diego CA 92121	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-08-12	43,513	$3.47	8,738,987	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2020-08-13	219,465	$3.65	8,958,452	No	4	P	Indirect	By LP
Common Stock	Acquisiton	2020-08-14	168,669	$3.88	9,127,121	No	4	P	Indirect	By LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP
No	4	P	Indirect	By LP

Footnotes

The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.415 to $3.54. TheReporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the ranges set forth in footnotes 1 and 3 through 4 herein.
The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.71.
The prices reported in Column 4 are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.685 to $3.95.